Dexcom Inc (DXCM) concluded trading on Thursday at a closing price of $84.1, with 4.78 million shares of worth about $401.75 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 6.23% during that period and on July 17, 2025 the price saw a loss of about -0.04%. Currently the company’s common shares owned by public are about 392.10M shares, out of which, 386.86M shares are available for trading.
Stock saw a price change of -1.59% in past 5 days and over the past one month there was a price change of 1.33%. Year-to-date (YTD), DXCM shares are showing a performance of -25.58% which increased to 8.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $57.52 but also hit the highest price of $117.19 during that period. The average intraday trading volume for Dexcom Inc shares is 3.61 million. The stock is currently trading 0.08% above its 20-day simple moving average (SMA20), while that difference is down -0.53% for SMA50 and it goes to 7.56% higher than SMA200.
Dexcom Inc (NASDAQ: DXCM) currently have 392.10M outstanding shares and institutions hold larger chunk of about 93.64% of that.
The stock has a current market capitalization of $32.98B and its 3Y-monthly beta is at 1.45. PE ratio of stock for trailing 12 months is 63.13, while it has posted earnings per share of $1.33 in the same period. Its PEG reads 2.63 and has Quick Ratio of 1.32 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DXCM, volatility over the week remained 2.52% while standing at 2.98% over the month.
Stock’s fiscal year EPS is expected to rise by 23.65% while it is estimated to increase by 25.53% in next year. EPS is likely to shrink at an annualized rate of 24.04% for next 5-years, compared to annual growth of 39.06% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on June 16, 2025 offering a Buy rating for the stock and assigned a target price of $102 to it. Coverage by Goldman stated Dexcom Inc (DXCM) stock as a Buy in their note to investors on May 30, 2025, suggesting a price target of $104 for the stock. On April 10, 2025, Mizuho Initiated their recommendations, while on February 03, 2025, Redburn Atlantic Upgrade their ratings for the stock with a price target of $115. Stock get an Outperform rating from Robert W. Baird on January 16, 2025.
